In late-stage cancer, cells seem to become resistant to its anti-mitotic effects and TGFB1 was instead observed to stimulate EMT by upregulating mesenchymal markers (e.g., VIM, CDH2) and downregulating epithelial markers (e.g., CDH1) [60]. This evidence concerns the gene CDH2 and cancer.